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Abstract 
Background: Damage to T cells of the immune system by reactive oxygen species may result 
in altered cell function or cell death and thereby potentially impact upon the efficacy of a 
subsequent immune response. Here, we assess the impact of the antioxidants Ebselen and N-
acetyl cysteine on a range of biological markers in human T cells derived from a SENIEUR 
status donor. In addition, the impact of these antioxidants on different MAP kinase pathways 
in T cells from donors of different ages was also examined. 
Methods: T cell clones were derived from healthy 26, 45 and SENIEUR status 80 year old 
people and the impact of titrated concentrations of Ebselen or N-acetyl cysteine on their 
proliferation and in vitro lifespan, GSH:GSSG ratio as well as levels of oxidative DNA 
damage and on MAP kinase signaling pathways was examined. 
Results: In this investigation neither Ebselen nor N-acetyl cysteine supplementation had any 
impact on the biological endpoints examined in the T cells derived from the SENIEUR status 
80 year old donor. This is in contrast to the anti-immunosenescent effects of these 
antioxidants on T cells from donors of 26 or 45 years of age. The analysis of MAP kinases 
showed that pro-apoptotic pathways become activated in T cells with increasing in vitro age 
and that Ebselen or N-acetyl cysteine could decrease activation (phosphorylation) in T cells 
from 26 or 45 year old donors, but not from the SENIEUR status 80 year old donor. 
Conclusions: The results of this investigation demonstrate that the biological phenotype of 
SENIEUR status derived human T cells negates the anti-immunosenescence effects of 
Ebselen and also N-acetyl cysteine. The results highlight the importance of pre-antioxidant 
intervention evaluation to determine risk-benefit. 
 
Abbreviations 
AP-1, Activator protein-1; CD, Cluster of differentiation; ERK, Extracellular signal regulated 
kinase; GSH, Reduced glutathione; GSSG, Oxidised glutathione; HK-2, Human kidney 
proximal tubule epithelial cells; JNK, c-Jun N-terminal kinase; ERK, Extracellular signal 
regulated kinases; MAP, Mitogen activated protein; NAC, N-Acetyl cysteine; PD, Population 
doubling; TCCs, T cell clones; TGHQ, 2,3,5-tris-(glutathion-S-yl)hydroquinone; PTKs, 
Protein tyrosine kinases; PTPs, Protein tyrosine phosphatases; Endo III, Endonuclease III; 
FPG, Formamidopyrimidine DNA glycosylase    
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1. Introduction   
T cells need to undergo rapid clonal expansion upon antigenic stimulation to produce an 
immune response. Any factor that interferes with the ability of T cells to clonally expand may 
impact on the effectiveness of an immune response with the potential to render it sub-optimal.  
Damage to T cells from reactive oxygen species (ROS), from both extrinsic and intrinsic 
(including sites of inflammation) sources may result in altered T cell function or T cell death 
[1,2]. Mammals have evolved defence systems, e.g. antioxidants and DNA repair systems, to 
help defend against the harmful effects of ROS [3]. Nonetheless these defence systems are not 
perfect, and can become overwhelmed. In addition we have established that DNA repair 
capacity declines with age in vivo [4] and in CD4+ T cell clones (TCCs) cultured in vitro 
[5,6]. This lack of optimal performance at all times by the defence systems may result in an 
accumulation of DNA damage to critical levels within T cells, resulting in cell cycle arrest or 
even apoptosis [7], with the potential to impact adversely on the T cell mediated immune 
response. 
Previous work from our group has provided evidence of an increase in the level of ROS-
induced DNA damage with age in CD4+ TCCs cultured at 20% O2 [3,8,9,10] and an increase 
in DNA damage and mutation with age in human lymphocytes [11]. A more recent study 
demonstrated anti-immunosenescence effects of two antioxidants, 2-phenyl-1,2-
benzisoselenazol-3 (2H)-one (Ebselen; [12]) or N-acetyl cysteine (NAC; [13]) on CD4+ TCCs 
derived from healthy 26 year old and 45 year old donors [10]. In this paper we now detail the 
impact of each of these two antioxidants on CD4+ TCCs derived from a healthy 80 year old 
donor (conforming to the SENIEUR protocol for healthily aged individuals; [14]). The 
SENIEUR protocol helps to ensure the rigorous selection of healthily aged individuals. 
Evidence from the literature suggests an age-associated compromise of T cell function [15]. 
An inverse relationship between replicative capacity and donor age of TCCs has previously 
been reported [16]. However, there are exceptions where a straightforward relationship 
between age and T cell function breaks down. T cells from very healthy elderly donors, 
including those selected using the SENIEUR protocol [14] is one exception. In these cases 
individuals have been shown to be able to raise an effective immune response, contributed to 
by adequate T cell function [17,18,19]. We were interested to examine whether the anti-
immunosenescent effects of Ebselen or NAC, which we have previously reported, in TCCs 
from donors of 26 or 45 years of age [10] were also present when TCCs from a SENIEUR 
selected healthy aged donor were tested. 
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Ebselen is a lipid soluble seleno-organic compound having glutathione peroxidase like 
activity which enables them to scavenge hydroxyl radicals and peroxides using glutathione 
(GSH) as a substrate [20]. Furthermore, Ebselen has the capability to inhibit the release of 
apoptotic factor cytochrome c [21]. The antioxidant potential of Ebselen has been previously 
demonstrated in a number of other cell lines; HepG2 cells [20], human HL-60 [22] and PC-12 
cells [23]. Their ability to scavenge intracellular ROS resulting in reduction of hydroxyl 
radical formation may have contributed to the antioxidant potential in TCCs derived from 
healthy 26 and 45 year old donors displayed by their impact on certain markers of T cell 
integrity and function [10]. 
In terms of NAC, the presence of acetylated form of the amino acid L-cysteine and sulfhydryl 
groups enables them to act as a precursor of GSH synthesis and neutralise free radicals 
respectively [24]. Glutamate and cysteine share the same transporter in the body and elevation 
in levels of extracellular glutamate competitively inhibit cysteine transport resulting in 
depletion of intracellular GSH synthesis. The ability of NAC to raise GSH levels due to its 
capacity to donate cysteine amino acid may also supplement its antioxidant potential [25]. 
Previous studies have revealed the ROS scavenging potential of NAC in HeLa cells [26] and 
HepG2 cells [20] 
Although they can cause damage within living systems, ROS act as signals/mediators in a 
variety of cellular processes including; cell function, proliferation, differentiation, cell damage 
and death. ROS act as intracellular signalling molecules within T cells [27], and they can 
mediate their effects via several signalling molecules such as calcium, protein tyrosine kinases 
(PTKs), protein tyrosine phosphatases (PTPs), serine/threonine kinases and phospholipases. 
ROS have been revealed to control cell proliferation induced by lectin and have an established 
role in protein tyrosine phosphorylation and activation of JNK1 [28]. Mitogen activated 
protein (MAP) kinases, a prominent family of protein kinases, operate through several 
pathways including, extracellular signal regulated kinases (ERK), c-Jun N-terminal kinase 
(JNK) and p38 kinase. These pathways are involved in proliferation, differentiation and 
apoptosis [23,29,30]. In the novel study described in this paper, the impact of Ebselen or NAC 
on different MAP kinase pathways in human CD4+ TCCs derived from healthy 26, 45 and 80 
year old donors has also been investigated in an attempt to understand the contributory factors 
to any alterations in the biological endpoints measured in the supplemented TCCs. 
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2. Materials and Methods  
2.1. Culture of TCCs and determination of their proliferative capacity and lifespan 
Clone 399-37 was derived from a healthy 80 year old donor (conforming to the SENIEUR 
protocol for healthily aged individuals; [14]), Clones 400-23 and 385-7 were derived from a 
healthy 26 and 45 year donor respectively. Three independently derived ([31] – general 
reference for deriving the TCCs) human CD4+ TCCs of each of the three donors were 
separately maintained in culture in 24 well plates (5 wells, 2 ml medium per well) containing 
serum-free medium, X-Vivo 10 (Bio Whittaker) at concentrations of 2-4 x 105 cells per well, 
along with 2 x 105 gamma-irradiated (80Gy) RJK853 cells per well (EBV-transformed B-
lymphoblastoid cell line with complete hprt deletion), as feeder cells. The clones were 
maintained at 37oC under conditions of 5% CO2 and 95% air atmosphere and supplemented 
with 400U/ml recombinant IL-2 (Chiron, UK) on days 1 and 4 of the 7 days cycle. A viable 
cell count was performed on harvested cells using a Neubauer Counting Chamber, and a new 
culture cycle was set up with fresh medium and RJK853 feeder cells on day 7 [3,8]. The 
proliferative capacity and lifespan were determined similar to the protocol described 
previously [3,8,10]. The TCCs used in this study were kindly provided by the group of 
Professor Graham Pawelec. 
 2.2. Ebselen or NAC supplementation of TCCs 
Further to our previous study [10] we examined the impact of titrated concentrations of 
Ebselen (0, 10, 30, 60, 100 M) or NAC (0, 1.25, 5, 7.5, 10 mM) in three pooled 399-37 (80 
year old) TCCs, 385-7 (45 year old) TCCs and 400-23 (26 year old) TCCs respectively. n=3 
in each case. 
2.3. Determination of levels of oxidative damage to DNA in TCCs derived from a healthy 
80 year old donor  
The levels and types of DNA damage in TCCs, supplemented with or without antioxidants, at 
various time points throughout their lifespan were assessed using a modified alkaline comet 
assay [3,8,10]. 
2.4. Quantitative determination of GSH:GSSG ratio and total glutathione level in TCCs 
derived from a healthy 80 year old donor 
A GSH:GSSG ratio assay kit was used to determine the ratio of reduced glutathione (GSH) to 
oxidized glutathione (GSSG), and total glutathione levels [10]. 
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2.5. Assessing the impact of antioxidant supplementation on MAP kinase signalling 
pathways in TCCs derived from donors of all three ages using SDS-polyacrylamide gel 
electrophoresis (PAGE) and Western Blotting  
Ebselen or NAC supplemented and non-supplemented clones were harvested at different 
stages of their lifespan (at different PDs). Cells were washed in 1xPBS (pH 7.4). To prepare 
samples for western blot, cells were counted in a Neubauer Counting Chamber and an 
appropriate amount of cells were re-suspended in loading buffer and incubated at 90oC for 10 
minutes. The samples were stored at -20oC and later used for SDS-PAGE. Loading buffer 
consists of 4% SDS, 40% Glycerin, 50mM Tris/HCL (pH 6.8), 50mM Dithiothreitol (DTT) 
and bromophenol blue. Whole cell extracts were electrophoresed on SDS-PAGE and 
transferred to nitrocellulose membranes (Protran; Schleicher and Schuell). The membrane was 
blocked in 5% skimmed milk/TBS-T (0.5 M Tris Base, 9 % NaCl, 0.5 % Tween 20, pH 8.4; 
Tween 20 [Carl Roth]) and incubated with protein-specific primary antibodies followed by 
horseradish peroxidase–conjugated species-specific secondary antibodies (Jackson 
ImmunoResearch Laboratories, Inc.). Signals were detected using the ECL reagent (GE 
Healthcare) on imaging film (BioMax; Kodak). Western Blot for Anti-β- Actin was 
performed as the loading control.  
2.5.1. Quantification of phosphorylated and total MAP kinase protein expression levels 
in TCC samples derived from donors for all the three ages  
For immunodetection, primary antibodies were used at the following dilutions: Phospho JNK 
(1:50; 9251), Phospho  p38 (1:100; 9211), Phospho  p44/p42 [ERK1/2] (1:500; 9101), 
Phospho c-Jun (1:50; 2361), SAPK / JNK (1:50; 9252), p38 (1:100; 9212), p44/p42 [ERK1/2] 
(1:600; 4695) and Anti-β- Actin (1:10,000; A5316). All antibodies except Anti-β-Actin were 
purchased from Cell Signaling Technology, Boston, USA. Anti-β-Actin was purchased from 
Sigma-Aldrich. Secondary antibodies, conjugated to horseradish peroxidase (Dako) were used 
at 1:10,000 dilution and blots developed using ECL detection system and radiographic film 
(GE Healthcare, Germany). After the film development, quantification of the signal intensities 
of the bands in the Western blots was carried out using the Metamorph software [32]. The 
signal intensities of the bands representing the levels of phosphorylated or total proteins were 
normalized to the reference band of Anti-β- Actin. 
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2.6. Statistical analysis of the samples 
The results were tested for significance using paired two-sample type 2 Student’s t-tests 
assuming equal variances; p values are presented as appropriate. 
3. Results 
3.1. Effects of Ebselen and NAC on intracellular redox status (GSH:GSSG ratio) and 
total glutathione levels in human TCCs in vitro derived from a healthy 80 year old donor 
TCC samples were taken from the cultures at various time points during their lifespan and the 
effect of 30 M Ebselen or 7.5 mM NAC on intracellular redox status (GSH:GSSG ratio) and 
total glutathione levels within the T cells were determined. Figs. 1A and 1B show the results 
of the effect of 30 M Ebselen or 7.5 mM NAC on the GSH:GSSG ratio. 
 
Figure 1. Impact of 30M Ebselen or 7.5mM NAC supplementation on GSH:GSSG ratio 
in TCCs derived from a healthy 80 year old donor. (A & B) The impact of 30 M Ebselen 
(1A) or 7.5mM NAC (1B) on GSH:GSSG ratio in three pooled TCCs derived from a healthy 
80 year old donor. The bars indicate the mean ± S.D.  
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Supplementation of TCCs from a young “in vitro age” with 30 M Ebselen (Fig. 1A) or 7.5 
mM NAC (Fig. 1B) had no impact on the GSH:GSSG ratio at any of the time points 
examined when compared to non-supplemented clones.  
In both cases (antioxidant supplemented and non-supplemented), the GSH:GSSG ratio 
significantly decreased with increased time in culture (Supplement Tables 1A and 1B). A 
similar scenario was observed in TCCs derived from a healthy 26 and 45 year old donor in 
our previous study [10]. Furthermore, the GSH:GSSG ratio was significantly lower in TCCs 
derived from a healthy 80 year old donor (supplemented and non-supplemented) compared to 
the GSH:GSSG ratio in TCCs derived from either of the healthy young aged donors (26 and 
45 year old; Tables 1A and 1B; [10]). 
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Table 1. (A) GSH:GSSG ratios in three pooled CD4+ TCCs (+ / - 30 M Ebselen) derived 
from a healthy 80 year old donor are significantly lower than in either of the three 
pooled TCCs, each derived from a healthy 26 or a 45 year old donor (published data 
from [10]). * Significantly lower GSH:GSSG ratio in 399-37 clones (80 year old) 
compared to either 400-23 (26 year old) or 385-7 (45 year old) clones. 
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Table 1. (B) GSH:GSSG ratios in three pooled CD4+ TCCs (+ / - 7.5 mM NAC) derived 
from a healthy 80 year old donor are significantly lower than the levels in either of the 
three pooled TCCs, each derived from a healthy 26 or a 45 year old donor (published 
data from [10]). * Significantly lower GSH:GSSG ratio in 399-37 clones (80 year old) 
compared to either 400-23 (26 year old) or 385-7 (45 year old) clones. 
 
Either concentration of Ebselen (30 M) or NAC (7.5 mM) investigated in this study had any 
impact on total glutathione levels, at any of the three time points in TCCs derived from a 
healthy 80 year old donor compared to non-supplemented clones, as was the case for 
GSH:GSSG ratio. However, the levels of total glutathione were significantly lower in the 399-
37 TCCs compared to levels in TCCs from both younger aged donors (Data not shown). 
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3.2. The impact of Ebselen and NAC on in vitro proliferative capacity and lifespan of 
human TCCs derived from a healthy 80 year old donor  
The TCCs used in this study underwent apoptosis at the end of their lifespan after completing 
a finite number of PDs. This is in line with previous reports [3,33]. 
The effect of different concentrations of Ebselen (0, 10, 30 M) or NAC (0, 1.25, 5, 7.5 mM) 
on the proliferative capacity and in vitro lifespan of TCCs was investigated by supplementing 
them with one of the either antioxidants until the end of their lifespan. The results presented in 
Tables 2A and 2B indicate that Ebselen (30 M) and NAC (7.5 mM) supplementation of 
TCCs derived from a healthy 80 year old donor resulted in a slight decrease in the average 
number of PD accomplished per week, though not statistically significant. Neither of the 
antioxidants had any significant impact on the cumulative level of PDs achieved before the 
end of their lifespan in the TCCs derived from a healthy 80 year old donor, in contrast to the 
significantly enhanced PDs in antioxidant supplemented TCCs derived from the healthy 
younger donors ([10]; Tables 2A and 2B). However, 30 M Ebselen or 7.5 mM NAC 
supplemented TCCs were able to survive in culture for an additional week and three weeks 
respectively compared to non-supplemented TCCs. Other concentrations investigated in the 
study, 10 M Ebselen and 1.25 or 5 mM NAC did not reveal an impact on either proliferative 
capacity or lifespan in TCCs derived from a healthy 80 year old donor. Higher concentrations 
of Ebselen (60-100 M) or NAC (10 mM) used in this investigation completely inhibited the 
growth of TCCs derived from a healthy 80 year old donor within a week of culture (Data not 
shown). A similar scenario was observed in our previous study when TCCs derived from a 
healthy 26 and 45 year old donor was supplemented with high concentrations of either 
Ebselen (60-100 M) or NAC (10 mM), [10]. Furthermore, as explained in our previous study 
[10], mechanisms behind the pro-apoptotic effect of high concentrations of antioxidants have 
also been demonstrated in other model systems [34,35,36].  
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Tables 2. (A and B) Effect of Ebselen (2A) or NAC (2B) supplementation on the 
proliferative capacity and lifespan of CD4+ TCCs derived from healthy 26, 45 or 80 year 
old donors. Data of 26 and 45 year old donors are published data from [10]. * 
Significantly higher cumulative PDs in supplemented (+) clones compared to controls (-). 
n=3 pooled TCCs for each age group 
 
3.3. The impact of Ebselen or NAC on levels of oxidative DNA damage in human TCCs 
as a function of in vitro age 
Aliquots of TCC samples were taken from culture at various time points and the effect of 30 
M of Ebselen or 7.5 mM of NAC on the levels of oxidative DNA damage within the T cells 
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were determined. In control (non-supplemented) samples, levels of oxidative damage to DNA 
increased as a function of age, as measured by the modified endonuclease III (Endo III) and 
formamidopyrimidine DNA glycosylase (FPG) comet assays, in line with previously 
published findings [3,9].  
The results presented in Figs. 2A and 2B reveal that oxidative DNA damage levels increased 
as a function of time in culture, in both supplemented and non-supplemented clones. Neither 
dose of antioxidants including 30 M for Ebselen and 7.5 mM for NAC had any impact on 
the levels of oxidative DNA damage in TCCs during their span in culture. Fig. 2 summarises 
the data obtained following 30 M Ebselen (A) or 7.5 mM NAC (B) supplementation. 
 
Figure 2. Effect of 30M Ebselen or 7.5mM NAC supplementation on the levels of 
oxidative DNA damage in TCCs derived from a healthy 80 year old donor. (A & B) The 
impact of 30 M Ebselen (2A) or 7.5mM NAC (2B) on the levels of oxidative DNA damage 
in three pooled TCCs derived from a healthy 80 year old donor. The bars indicate the mean ± 
S.D.  
The levels of oxidative DNA damage significantly increased with time in culture in both 
supplemented and non-supplemented TCCs derived from a healthy 80 year old donor (Tables 
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3A & 3B). This was also the case in TCCs derived from a healthy 26 or 45 year old donor 
[10]. A comparison of the levels of oxidative DNA damage in the 399-37 clone samples with 
those from the younger donors revealed that basal levels of oxidative DNA damage were 
significantly higher (+/- supplementation) after all sampled time points (Supplement Tables 
2A and 2B). 
Tables 3. (A and B) The increase in levels of oxidative DNA damage in CD4+ TCC 
derived from a healthy 80 year old donor supplemented with / without 30 M Ebselen 
(3A) or 7.5 mM NAC (3B). * Significantly higher levels of oxidative DNA damage in 
week 10 on comparison with the earlier weeks (2 and 5). n=3 pooled TCCs for each age 
group 
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3.4. The impact of Ebselen or NAC on different MAP kinase pathways in human TCCs 
derived from donors of different ages 
The impact of Ebselen or NAC supplementation on MAP kinase phosphorylation status and 
total protein levels was determined in TCC samples from healthy young (26 year old), middle 
aged (45 year old) and elderly (80 year old) donors. 
 
Figure 3. (A) The impact of 30 M Ebselen on the phosphorylation levels of JNK, c-Jun, 
p38 and ERK between the young (early PD) and aged (late PD) TCCs isolated from healthy 
26, 45 or 80 year old donors. 
Fig. 3A reveals that ERK was similarly phosphorylated in Ebselen supplemented or control 
TCCs, irrespective of TCC in vitro age (PD). In contrast, JNK, p38 and c-Jun phosphorylation 
levels were absent (or low) in young cells (Y) but greatly enhanced in late PD cells (O) from 
all donors. 30 M Ebselen did not significantly alter the increase of p38 phosphorylation in 
late PD TCCs. There was a significant reduction in JNK and c-Jun phosphorylation in young 
and middle-aged donor TCCs on Ebselen supplementation. However, Ebselen did not result in 
a reduction in JNK or c-Jun phosphorylation in TCCs derived from a healthy 80 year old 
donor (80, O, +). Quantification of the signal intensities of the bands in the Western blots 
were performed for both supplemented and non-supplemented clones (Supplement Figs. 1A-
1L). 
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Figure 3. (B) The impact of 30 M Ebselen on the phosphorylation levels of JNK, c-Jun, 
p38 and ERK between the young (early PD) and aged (late PD) TCCs isolated from 
healthy 26, 45 or 80 year old donors. 
A similar pattern of phosphorylation is seen in the young (early PD) TCCs with and without 
7.5 mM NAC supplementation, with only ERK phosphorylated to any significant extent (Fig. 
3B). Phosphorylation of JNK, p38 and c-Jun was absent (or low) in young cells (Y) but 
greatly enhanced in aged cells (O) from all donors. 7.5 mM NAC supplementation inhibited 
this phosphorylation by at least 80% (Fig. 3B) in young (26 year old) and middle aged (45 
year old) donor TCCs with the exception of p-JNK in the middle aged donor TCC where a 
lower reduction was seen (~25%). However, no significant reduction in phosphorylation of 
JNK, p38, and c-Jun was found in TCCs derived from a healthy 80 year old donor treated 
with 7.5 mM NAC (80, O, +). Quantification of the signal intensities of the bands in the 
Western blots were performed for both supplemented and non-supplemented clones 
(Supplement Figs. 2A-2L). 
The total levels of JNK, p38 and ERK (Supplement Figs. 3C and 3D) were not significantly 
different following 30 M Ebselen or 7.5 mM NAC, compared to non-supplemented controls. 
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4. Discussion 
Previous work from our group demonstrated the anti-immunosenescence potential of certain 
concentrations of Ebselen (30 M) or NAC (7.5 mM) in CD4+ T cells ex vivo and in CD4+ 
TCCs when supplemented from a young in vitro age [10]. The ROS scavenging potential of 
these antioxidants resulted in enhancement of the GSH:GSSG ratio, a significant decrease in 
levels of oxidative DNA damage and a significant increase in lifespan, and/or proliferative 
capacity of TCCs derived from a healthy 26 year old or 45 year old donor.  
In contrast, in the present study, supplementation of a TCC derived from a healthy 80 year old 
donor (conforming to the SENIEUR protocol; [14]) with 30 M Ebselen or 7.5 mM NAC, 
from a young in vitro age (31.1 Initial PD) did not significantly alter the lifespan, the 
proliferative capacity (Tables 2A and 2B), levels of oxidative DNA damage (Figs. 2A and 
2B), intracellular redox status (GSH:GSSG ratio; Figs. 1A and 1B) or the total glutathione 
levels.  
Barnett and colleagues have previously published that 20 mM Carnosine (an antioxidant) 
supplementation from the midpoint of their in vitro lifespan did not alter the longevity of 
TCCs derived from an 80 year old donor [3]. In that case, it was suggested that Carnosine 
may not have been able to reveal its antioxidant potential due to the high background of 
biomolecule damage that already existed in these T cells, accumulated during earlier stages of 
their in vitro lifespan under conditions of 20% O2 that may have compromised a range of 
intracellular systems. One piece of evidence in this regard is the measured increase in basal 
levels of oxidative DNA in TCCs from a healthy 80 year old donor, compared with basal 
levels in TCCs from healthy 26 or 45 year old donors (Supplement Tables 2A and 2B). The 
results obtained in this current investigation suggest that a range of antioxidant 
supplementations do not have an impact on the biological endpoints measured in the TCCs 
from healthy 80 year old donors.  
A similar scenario is applicable in terms of the GSH:GSSG ratio. Intracellular redox status (as 
reflected in the GSH:GSSG ratio) is an important mechanism having an invaluable role as a 
mediator in apoptosis in many cell systems [37]. Previous findings reveal that intracellular 
reduced glutathione (GSH), a main determinant of intracellular redox status, is depleted 
before the onset of apoptosis [38]. The GSH:GSSG redox couplet maintains the redox 
environment of the cell and GSH is abundant in the cell [39]. The oxidation of even a small 
amount of GSH results in the formation of GSSG thereby lowering the GSH:GSSG ratio 
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suggested to be responsible for several human diseases [40]. However, in this study, the 
GSH:GSSG ratio did not significantly change on antioxidant supplementation compared to 
the non-treated controls, and the ratio decreased as cells approached the latter stage of their in 
vitro lifespan. 
Although ROS are generally thought of as harmful molecules, they do play an important role 
in T cell signalling events [41] including the MAP kinase pathways. MAP kinases have 
several pathways identified including ERK, JNK and the p38 kinase pathways. ERK 
phosphorylation has been shown to act as a cell survival factor against oxidative stress, 
whereas phosphorylation of JNK and p38 contributes to cell death machinery [23]. T cell 
signalling events such as protein tyrosine phosphorylation and activation of JNK as well as 
cellular proliferation induced by lectin are some of the few instances that require the presence 
of ROS [28]. Reduced ROS levels might interfere with the signalling pathways involved in T 
cell activation and proliferation, for example, the redox-sensitive activation of transcription 
factors such as nuclear factor kappa light chain enhancer of activated B cells (NF-kB) or 
activator protein-1 (AP-1) [42].  
This paper describes the investigation of the effect of the antioxidants, Ebselen or NAC, on 
the phosphorylation of p38 and JNK (SAPK) in TCCs from donors of different ages. JNK 
activation primarily results in apoptosis by the phosphorylation of c-Jun (serine 63), which is 
a component of the transcription factor complex AP-1 that binds to a specific DNA sequence 
in the AP-1 site [43] resulting in increase of DNA binding and ultimately apoptosis. Previous 
findings have indicated inhibition of H2O2-induced p38 MAP kinase activation, c-Jun 
phosphorylation and JNK activation by Ebselen in a concentration-dependent manner [23]. 
Furthermore, earlier studies have revealed that NAC decreased both JNK and p38 
phosphorylation induced by 2,3,5-tris-(glutathion-S-yl)hydroquinone (TGHQ) in human 
epithelial cells [44], selenite in hepatocytes [29]  and taxol (chemotherapeutic agent) in 
leukaemic cells [30]. The results of the present study suggest that pro-apoptotic pathways 
become activated in all TCCs as the cells reach an ‘old’ in vitro age with activation of JNK, 
p38 and c-Jun across all old TCCs irrespective of donor age (Figs. 3A and 3B). The results of 
our study also reinforce the radical scavenging potential of Ebselen and NAC with a 
significant decrease in phosphorylation of JNK and c-Jun in late PD TCCs in vitro derived 
from a healthy 26 or 45 year old donor on supplementation with 30 M Ebselen (Fig. 3A) or 
7.5 mM NAC (Fig. 3B) compared to non-supplemented TCCs, although only NAC 
supplementation was able to decrease p38 phosphorylation in these late PD TCCs. However, 
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neither antioxidant could significantly alter phosphorylation of p38, JNK or c-Jun in late PD 
TCCs in vitro derived from a healthy 80 year old donor (Figs. 3A and 3B). Our results suggest 
that neither Ebselen nor NAC could alter the activation of p38, JNK and c-Jun in TCCs from 
very healthy elderly donors and thus fail to impact upon the time to onset of apoptosis. This is 
another piece of evidence which suggests that there are alterations to intracellular processes, 
which have accumulated during the prolonged existence of T cells from elderly donors.  
In contrast to the results obtained from our study, others have published that NAC 
supplementation increased ERK activation in human kidney proximal tubule epithelial cells 
(HK-2) [44]. However, results from this present study revealed consistent activation of ERK 
in all TCCs irrespective of donor or in vitro age with no significant change in the levels of 
ERK phosphorylation in any of the age groups upon supplementation with either 30 M 
Ebselen or 7.5 mM NAC, compared to non-supplemented TCCs (Figs. 3A and 3B). 
The results of this study highlight a heterogeneous potential of Ebselen or NAC as anti-
immunosenescent interventive strategies in human T cells. If in vivo antioxidant 
supplementation is to be attempted then careful pre-intervention evaluation should be 
undertaken to determine risk-benefit. 
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Supplement Section 
Supplement Table 1. (A and B) The decrease in levels of GSH:GSSG ratio in CD4+ 
TCCs derived from an 80 year old donor with age when supplemented with / without 30 
M Ebselen (A) or 7.5 mM NAC (B) . * Significantly lower GSH:GSSG ratio in week 10 
in comparison with weeks 2 and 5. n=3 pooled TCCs for each age group 
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Supplement Table 2. (A) The levels of oxidative DNA damage in three pooled CD4+ 
TCCs (+ / - 30 M Ebselen) derived from an 80 year old donor was significantly higher 
than the levels in three pooled TCCs, derived from either 26 or 45 year old donor (both 
published data from [10]). * Significantly higher levels of oxidative DNA damage in 399-
37 clones (80 year old) compared to both 400-23 (26 year old) and 385-7 (45 year old) 
clones. 
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Supplement Table 2. (B) The levels of oxidative DNA damage in three pooled CD4+ 
TCCs (+ / - 7.5 mM NAC) derived from an 80 year old donor was significantly higher 
than the levels in three pooled TCCs, derived from either 26 or 45 year old donor (both 
published data from [10]). * Significantly higher levels of oxidative DNA damage in 399-
37 clones (80 year old) compared to both 400-23 (26 year old) and 385-7 (45 year old) 
clones. 
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Supplement Figure 1. (A-D) Comparison of mean fold change of protein expression levels of p-
JNK (A), p-ERK (B), p-p38 (C) and c-Jun (D) in early PD (young) and late PD (old) TCCs 
(derived from a 26 yr old donor) supplemented with 30 M Ebselen compared to controls. In all 
the above figures, the intensity of the bands of old PD TCCs (- Ebselen treatment) were assigned 1. 
Samples were analysed in triplicate. The bars indicate the mean ± S.D. Young PD TCCs (+ / - 
Ebselen) and old PD TCCs (+ Ebselen) were compared to old PD TCCs (- Ebselen) using Student’s t-
test and values statistically different to old PD TCCs (- Ebselen) are indicated with an asterix: *** p < 
0.001 - significantly different compared to old TCCs (- Ebselen) with PD assigned 1.  
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Supplement Figure 1. (E-H) Comparison of mean fold change of protein expression levels of p-
JNK (E), p-ERK (F), p-p38 (G) and c-Jun (H) in early PD (young) and late PD (old) TCCs 
(derived from a 45 yr old donor) supplemented with 30 M Ebselen compared to controls. In all 
the above figures, the intensity of the bands of old PD TCCs (without Ebselen treatment) were 
assigned 1. Samples were analysed in triplicate. The bars indicate the mean ± S.D. Young PD TCCs (+ 
/ - Ebselen) and old PD TCCs (+ Ebselen) were compared to old PD TCCs (- Ebselen) using Student’s 
t-test and values statistically different to old PD TCCs (- Ebselen) are indicated with an asterix: *** p 
< 0.001 - significantly different compared to old TCCs (- Ebselen) with PD assigned 1.  
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Supplement Figure 1. (I-L) Comparison of mean fold change of protein expression levels of p-
JNK (I), p-ERK (J), p-p38 (K) and c-Jun (L) in early PD (young) and late PD (old) TCCs 
(derived from a 80 yr old donor) supplemented with 30 M Ebselen compared to controls. In all 
the above figures, the intensity of the bands of old PD TCCs (- Ebselen treatment) were assigned 1 
whereas in figure 1J, intensity of the bands of old PD TCCs (+ Ebselen treatment) was assigned 1. 
Samples were analysed in triplicate. The bars indicate the mean ± S.D. Young PD TCCs (+ / - 
Ebselen) and old PD TCCs (+ Ebselen) were compared to old PD TCCs (- Ebselen) using Student’s t-
test except for figure 1J where old PD TCCs (+ Ebselen) was assigned as the template to be compared. 
The values statistically different to old PD TCCs (- Ebselen) with the exception of figure 1J are 
indicated with an asterix: *** p < 0.001 - significantly different compared to old TCCs (- Ebselen) 
with PD assigned 1 except for figure 1J where old PD TCCs (+ Ebselen) was assigned the value 1. 
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Supplement Figure 2. (A-D) Comparison of mean fold change of protein expression levels of p-
JNK (A), p-ERK (B), p-p38 (C) and c-Jun (D) in early PD (young) and late PD (old) TCCs 
(derived from a 26 yr old donor) supplemented with 7.5 mM NAC compared to controls. In all 
the above figures, the intensity of the bands of old PD TCCs (without NAC treatment) were assigned 
1. Samples were analysed in triplicate. The bars indicate the mean ± S.D. Young PD TCCs (+ / - 
NAC) and old PD TCCs (+ NAC) were compared to old PD TCCs (- NAC) using Student’s t-test and 
values statistically different to old PD TCCs (- NAC) are indicated with an asterix: *** p < 0.001 - 
significantly different compared to old TCCs (- NAC) with PD assigned 1.  
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Supplement Figure 2. (E-H) Comparison of mean fold change of protein expression levels of p-
JNK (E), p-ERK (F), p-p38 (G) and c-Jun (H) in early PD (young) and late PD (old) TCCs 
(derived from a 45 yr old donor) supplemented with 7.5 mM NAC compared to controls. In all 
the above figures, the intensity of the bands of old PD TCCs (without NAC treatment) were assigned 
1. Samples were analysed in triplicate. The bars indicate the mean ± S.D. Young PD TCCs (+ / - 
NAC) and old PD TCCs (+ NAC) were compared to old PD TCCs (- NAC) using Student’s t-test and 
values statistically different to old PD TCCs (- NAC) are indicated with an asterix: *** p < 0.001 - 
significantly different compared to old TCCs (- NAC) with PD assigned 1.  
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Supplement Figure 2. (I-L) Comparison of mean fold change of protein expression levels of p-
JNK (I), p-ERK (J), p-p38 (K) and c-Jun (L) in early PD (young) and late PD (old) TCCs 
(derived from a 80 yr old donor) supplemented with 7.5 mM NAC compared to controls. In all 
the above figures, the intensity of the bands of old PD TCCs (without NAC treatment) were assigned 
1. Samples were analysed in triplicate. The bars indicate the mean ± S.D. Young PD TCCs (+ / - 
NAC) and old PD TCCs (+ NAC) were compared to old PD TCCs (- NAC) using Student’s t-test and 
values statistically different to old PD TCCs (- NAC) are indicated with an asterix: *** p < 0.001 - 
significantly different compared to old TCCs (- NAC) with PD assigned 1.  
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Supplement Figure 3. (C) The impact of 30 M Ebselen on the total levels of JNK, ERK and p38 
between the young (early PD) and aged (late PD) CD4+ TCCs isolated from healthy 26, 45 or 80 
year old donors compared to the non-supplemented young (early PD) and old aged (late PD) TCCs. 
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Supplement Figure 3. (D) The impact of 7.5 mM NAC on the total levels of JNK, ERK and p38 
between the young (early PD) and aged (late PD) CD4+ TCCs isolated from healthy 26, 45 or 80 
year old donors compared to the non-supplemented young (early PD) and old aged (late PD) TCCs. 
 
 
 
 
 
 
